Observational studyAmerican journal of hematology2024

Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.

Matthew A Lunning et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.